Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis.
Beuselinck B, Karadimou A, Lambrechts D, Claes B, Wolter P, Couchy G, Berkers J, van Poppel H, Paridaens R, Schöffski P, Méjean A, Verkarre V, Lerut E, Joly F, Lebret T, Gravis G, Deplanque G, Descazeaud A, Leclercq NR, Molinié V, Patard JJ, Teghom C, Elaidi R, Zucman-Rossi J, Oudard S. Beuselinck B, et al. Among authors: karadimou a. Acta Oncol. 2014 Jan;53(1):103-12. doi: 10.3109/0284186X.2013.770600. Epub 2013 Feb 20. Acta Oncol. 2014. PMID: 23421954
Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases.
Beuselinck B, Wolter P, Karadimou A, Elaidi R, Dumez H, Rogiers A, Van Cann T, Willems L, Body JJ, Berkers J, Van Poppel H, Lerut E, Debruyne P, Paridaens R, Schöffski P. Beuselinck B, et al. Among authors: karadimou a. Br J Cancer. 2012 Nov 6;107(10):1665-71. doi: 10.1038/bjc.2012.385. Br J Cancer. 2012. PMID: 23132391 Free PMC article.
Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib.
Beuselinck B, Karadimou A, Lambrechts D, Claes B, Wolter P, Couchy G, Berkers J, Paridaens R, Schöffski P, Méjean A, Verkarre V, Lerut E, de la Taille A, Tourani JM, Bigot P, Linassier C, Négrier S, Berger J, Patard JJ, Zucman-Rossi J, Oudard S. Beuselinck B, et al. Among authors: karadimou a. Br J Cancer. 2013 Mar 5;108(4):887-900. doi: 10.1038/bjc.2012.548. Br J Cancer. 2013. PMID: 23462807 Free PMC article.
Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib.
Beuselinck B, Vano YA, Oudard S, Wolter P, De Smet R, Depoorter L, Teghom C, Karadimou A, Zucman-Rossi J, Debruyne PR, Van Poppel H, Joniau S, Lerut E, Strijbos M, Dumez H, Paridaens R, Van Calster B, Schöffski P. Beuselinck B, et al. Among authors: karadimou a. BJU Int. 2014 Jul;114(1):81-9. doi: 10.1111/bju.12494. Epub 2014 Jan 15. BJU Int. 2014. PMID: 24215209
Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib.
Beuselinck B, Lambrechts D, Van Brussel T, Wolter P, Cardinaels N, Joniau S, Lerut E, Karadimou A, Couchy G, Sebe P, Ravaud A, Zerbib M, Caty A, Paridaens R, Schöffski P, Verkarre V, Berger J, Patard JJ, Zucman-Rossi J, Oudard S. Beuselinck B, et al. Among authors: karadimou a. Acta Oncol. 2014 Oct;53(10):1413-22. doi: 10.3109/0284186X.2014.918276. Epub 2014 May 30. Acta Oncol. 2014. PMID: 24874929
Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting.
Beuselinck B, Job S, Becht E, Karadimou A, Verkarre V, Couchy G, Giraldo N, Rioux-Leclercq N, Molinié V, Sibony M, Elaidi R, Teghom C, Patard JJ, Méjean A, Fridman WH, Sautès-Fridman C, de Reyniès A, Oudard S, Zucman-Rossi J. Beuselinck B, et al. Among authors: karadimou a. Clin Cancer Res. 2015 Mar 15;21(6):1329-39. doi: 10.1158/1078-0432.CCR-14-1128. Epub 2015 Jan 12. Clin Cancer Res. 2015. PMID: 25583177 Free article.
Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model.
Bamias A, Karadimou A, Lampaki S, Lainakis G, Malettou L, Timotheadou E, Papazisis K, Andreadis C, Kontovinis L, Anastasiou I, Stravodimos K, Xanthakis I, Skolarikos A, Christodoulou C, Syrigos K, Papandreou C, Razi E, Dafni U, Fountzilas G, Dimopoulos MA. Bamias A, et al. Among authors: karadimou a. BMC Cancer. 2010 Feb 18;10:45. doi: 10.1186/1471-2407-10-45. BMC Cancer. 2010. PMID: 20163744 Free PMC article.
Association of ERCC1 SNPs with outcome in platinum-treated patients with advanced urothelial cancer: a Hellenic Cooperative Oncology Group study.
Nikitas N, Karadimou A, Tsitoura E, Soupos N, Tsiatas M, Karavasilis V, Pectasides D, Pavlidis N, Chrisofos M, Adamakis I, Murray S, Fountzilas G, Dimopoulos MA, Bamias A. Nikitas N, et al. Among authors: karadimou a. Pharmacogenomics. 2012 Nov;13(14):1595-607. doi: 10.2217/pgs.12.162. Pharmacogenomics. 2012. PMID: 23148636
Clinical Outcomes Beyond 1L EGFR-TKI Progression in mNSCLC: Final Results of the Real-World Study 'LUNGFUL'.
Mountzios G, Koumarianou A, Linardou H, Boutis A, Mavroudis D, Samantas E, Korantzis I, Athanasiadis E, Fergadis EG, Lampaki S, Georgoulias V, Baka S, Karamouzis MV, Boukovinas I, Andreadis C, Rapti A, Koulouris N, Pentheroudakis G, Froudarakis ME, Somarakis A, Anastasopoulou E, Karadimou A, Papageorgiou F, Paparepa Z, Nikolaou A, Papista C, Syrigos KN. Mountzios G, et al. Among authors: karadimou a. Anticancer Res. 2023 May;43(5):2243-2258. doi: 10.21873/anticanres.16388. Anticancer Res. 2023. PMID: 37097667
25 results